Posted by & filed under Company Analysis, Financial Planning, Governments & Regulators, Growth & Valuation, Industry Analysis, Management Issues.

Description:   People in developing countries worldwide will continue to have access to low-cost copycat versions of drugs for diseases like H.I.V. and cancer, at least for a while.

Source:  NYTimes.com

Date: Apr 01, 2013

Link: http://www.nytimes.com/2013/04/02/business/global/top-court-in-india-rejects-novartis-drug-patent.html?_r=0

Questions for Discussions:

  • What is the basis for the decision?
  • Do you think this will become a growing financial issue for pharmaceutical companies?
  • How might the industry respond if more and more patent decisions go against them?
  • What are the ethical and social responsibility implications for this trend?
  • What are other formulas for funding research into new drugs?

Leave a Reply

Your email address will not be published.